These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38761668)

  • 1. Continuity of treatment in ALS: Benefits and challenges of maintaining riluzole over the course of the disease.
    Silani V
    J Neurol Sci; 2024 Jun; 461():123038. PubMed ID: 38761668
    [No Abstract]   [Full Text] [Related]  

  • 2. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of amyotrophic lateral sclerosis with riluzole.
    Neatherlin JS
    J Neurosci Nurs; 1998 Aug; 30(4):257-60. PubMed ID: 9791781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole treatment in advanced ALS.
    Borasio GD
    J Neurol; 2002 May; 249(5):505-6. PubMed ID: 12021937
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for a multimodal effect of riluzole in patients with ALS?
    de Jongh AD; van Eijk RPA; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1183-1184. PubMed ID: 30846539
    [No Abstract]   [Full Text] [Related]  

  • 7. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme.
    Meyer T; Kettemann D; Maier A; Grehl T; Weyen U; Grosskreutz J; Steinbach R; Norden J; George A; Hermann A; Guenther R; Petri S; Schreiber-Katz O; Dorst J; Ludolph AC; Walter B; Münch C; Spittel S
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):783-785. PubMed ID: 32317400
    [No Abstract]   [Full Text] [Related]  

  • 8. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole use during pregnancy in a patient with amyotrophic lateral sclerosis: a case report.
    Kawamichi Y; Makino Y; Matsuda Y; Miyazaki K; Uchiyama S; Ohta H
    J Int Med Res; 2010; 38(2):720-6. PubMed ID: 20515588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole--what is its impact in our treatment and understanding of amyotrophic lateral sclerosis?
    Mitsumoto H
    Ann Pharmacother; 1997 Jun; 31(6):779-81. PubMed ID: 9184724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing a patient's decision regarding riluzole: an early experience.
    Rudnicki SA
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.
    Vucic S; Lin CS; Cheah BC; Murray J; Menon P; Krishnan AV; Kiernan MC
    Brain; 2013 May; 136(Pt 5):1361-70. PubMed ID: 23616585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].
    Kollewe K; Dengler R; Petri S
    Nervenarzt; 2008 Jun; 79(6):653-61. PubMed ID: 18210046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
    Nygren I; Antonova K; Mattsson P; Askmark H
    Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of ALS.
    Münch C; Ludolph AC
    Neurol Neurochir Pol; 2001; 35(1 Suppl):41-50. PubMed ID: 11732279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.